Home » Stocks » Cerus

Cerus Corporation (CERS)

Stock Price: $7.06 USD -0.04 (-0.56%)
Updated Aug 7, 2020 4:00 PM EDT - Market closed
After-hours: $7.20 +0.14 (1.98%) Aug 7, 7:38 PM

Stock Price Chart

Key Info

Market Cap 1.17B
Revenue (ttm) 79.05M
Net Income (ttm) -66.23M
Shares Out 166.17M
EPS (ttm) -0.44
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 7, 2020
Last Price $7.06
Previous Close $7.10
Change ($) -0.04
Change (%) -0.56%
Day's Open 7.22
Day's Range 7.00 - 7.23
Day's Volume 1,185,776
52-Week Range 2.71 - 7.56

More Stats

Market Cap 1.17B
Enterprise Value 1.10B
Earnings Date (est) Oct 29, 2020
Ex-Dividend Date n/a
Shares Outstanding 166.17M
Float 150.45M
EPS (basic) -0.44
EPS (diluted) -0.44
FCF / Share -0.38
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 10.49M
Short Ratio 4.88
Short % of Float 6.61%
Beta 1.29
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 14.84
PB Ratio 10.30
Revenue 79.05M
Operating Income -63.38M
Net Income -66.23M
Free Cash Flow -61.71M
Net Cash 75.08M
Net Cash / Share 0.45
Gross Margin 52.16%
Operating Margin -80.17%
Profit Margin -65.70%
FCF Margin -78.06%
ROA -20.31%
ROE -73.52%
ROIC -36.00%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (4)

Buy 4
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

(29.18% upside)
Current: $7.06
Target: 9.12
*Average 12-month price target from 4 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Revenue Growth23.3%48.17%30.68%14.76%-6.02%-8.17%8.07%19.91%41.17%-
Gross Profit60.3644.4228.8018.9810.7615.2317.0616.0812.079.63
Operating Income-66.23-54.99-57.53-61.45-61.08-44.50-28.30-17.39-18.37-17.39
Net Income-71.24-57.56-60.59-62.91-55.87-38.76-43.34-15.92-16.98-16.91
Shares Outstanding14013210810296.0774.7767.5754.5248.0540.30
Earnings Per Share-0.51-0.44-0.56-0.62-0.61-0.61-0.64-0.33-0.35-0.42
Operating Cash Flow-65.84-31.25-52.24-53.53-51.13-39.81-26.66-13.92-15.63-14.27
Capital Expenditures-8.94-1.14-0.35-0.56-0.72-2.08-0.66-0.08-0.16-1.69
Free Cash Flow-74.77-32.39-52.59-54.09-51.85-41.89-27.33-14.00-15.79-15.96
Cash & Equivalents88.1512060.9471.8110851.8057.9827.0026.0930.31
Total Debt64.4529.8729.8019.3819.809.873.377.727.224.89
Net Cash / Debt23.7090.4431.1552.4488.6941.9354.6219.2818.8725.42
Book Value57.0584.5238.9457.7994.7741.5242.8019.1118.3123.73
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Cerus Corporation
Country United States
Employees 254
CEO William Mariner Greenman

Stock Information

Ticker Symbol CERS
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: CERS
IPO Date January 30, 1997


Cerus Corporation, a biomedical products company, focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma that is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; and INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion. It sells platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. The company has a collaboration with the National Trauma Institute to supply Intercept plasma for use in the plasma resuscitation without lung injury (PROpOLIs) clinical study. Cerus Corporation was founded in 1991 and is headquartered in Concord, California.